Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 33
Filter
1.
Auris Nasus Larynx ; 51(3): 575-582, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38547566

ABSTRACT

OBJECTIVE: Transoral surgery is a minimally invasive treatment but may cause severe dysphagia at a lower rate than chemoradiotherapy. METHODS: We compared clinical information, surgical complications, and swallowing function in patients who underwent transoral nonrobotic surgery for laryngo-pharyngeal squamous cell carcinoma between 2015 and 2021 in a multicenter retrospective study. RESULTS: Six hundred and forty patients were included. Postoperative bleeding was observed in 20 cases (3.1%), and the risk factor was advanced T category. Postoperative laryngeal edema was observed in 13 cases (2.0%), and the risk factors were prior radiotherapy, advanced T stage, and concurrent neck dissection in patients with resected HPC. Dysphagia requiring nutritional support was observed in 29 cases (4.5%) at 1 month postoperatively and in 19 cases (3.0%) at 1 year postoperatively, respectively. The risk factors for long-term dysphagia were prior radiotherapy and advanced T category. Short-term risk factors for dysphagia were prior radiotherapy, advanced T category, and concurrent neck dissection, while long-term risk factors for dysphagia were only prior radiotherapy and advanced T category. CONCLUSION: Prior radiotherapy, advanced T stage, and concurrent neck dissection increased the incidence of postoperative laryngeal edema and short-term dysphagia, but concurrent neck dissection did not affect long-term dysphagia. Such features should be considered when considering the indication for transoral surgery and postoperative management.


Subject(s)
Deglutition Disorders , Laryngeal Neoplasms , Neck Dissection , Pharyngeal Neoplasms , Postoperative Complications , Humans , Male , Retrospective Studies , Deglutition Disorders/etiology , Female , Laryngeal Neoplasms/surgery , Middle Aged , Aged , Postoperative Complications/epidemiology , Pharyngeal Neoplasms/surgery , Risk Factors , Squamous Cell Carcinoma of Head and Neck/surgery , Neoplasm Staging , Adult , Laryngeal Edema/etiology , Carcinoma, Squamous Cell/surgery , Postoperative Hemorrhage/epidemiology , Aged, 80 and over , Natural Orifice Endoscopic Surgery
2.
Acta Otolaryngol ; 144(1): 82-89, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38362716

ABSTRACT

PURPOSE: Mucosal melanoma of the head and neck (MMHN) is a rare condition. This study aimed to investigate oncological outcomes of surgical intervention in patients with MMHN. MATERIALS AND METHODS: The study included 34 patients with MMHN who underwent surgical resection as initial treatment at 10 institutions in Japan between July 2005 and June 2015. Results: The 5-year overall survival (OS), local control rate (LCR), disease-free survival (DFS), and disease-specific survival (DSS) rates were 48.7%, 53.4%, 32.4%, and 55.1%, respectively. Based on multivariate analysis, no independent prognostic factors for the 5-year OS and DSS were found. Based on univariate analysis, the 5-year LCR was worse in patients with lesions in the nasal cavity and paranasal sinuses than in the oral cavity and pharynx. However, no differences in oncological outcomes were identified in relation to primary sites, and postoperative radiotherapy (PORT) and adjuvant systemic therapy did not contribute to improvements in the 5-year OS. CONCLUSIONS: No independent prognostic factors for the 5-year OS or DSS were identified. Regional or distant recurrences are often identified, regardless of local control with surgical resection. Difficult control of MMHN with conventional therapeutic strategies, such as surgical intervention, PORT, and systemic therapy, has been suggested.


Subject(s)
Head and Neck Neoplasms , Melanoma , Paranasal Sinuses , Humans , Retrospective Studies , Melanoma/surgery , Melanoma/pathology , Japan/epidemiology , Head and Neck Neoplasms/surgery , Paranasal Sinuses/pathology , Survival Rate , Neoplasm Recurrence, Local/epidemiology , Neoplasm Recurrence, Local/pathology , Prognosis
3.
Head Neck ; 2024 Jan 31.
Article in English | MEDLINE | ID: mdl-38294099

ABSTRACT

BACKGROUND: Hypopharyngeal carcinoma is likely to spread to the lymph nodes, but there is no established strategy for management in transoral surgery. METHODS: We compared oncologic and functional outcomes in a retrospective multicenter study of patients who underwent transoral surgery for hypopharyngeal carcinoma between 2015 and 2021. RESULTS: Two-hundred and thirty-two patients were included. Comparing patients with and without adjuvant radiotherapy, 3-year regional recurrence-free survival (RRFS) was not significantly different in pN2b and pN2c, but was significantly worse in pN3b without adjuvant radiotherapy. In patients without neck dissection, the 3-year RRFS was 85.6%, 76.8%, and 70.0% for T1, T2, and T3 primary lesions, respectively, and was significantly worse for T2 or higher (p = 0.035). CONCLUSIONS: In the absence of extracapsular invasion, regional control did not deteriorate without adjuvant therapy. If prophylactic neck dissection is not performed, careful follow-up is necessary if the primary lesion is T2 or greater.

4.
Auris Nasus Larynx ; 51(1): 86-98, 2024 Feb.
Article in English | MEDLINE | ID: mdl-37248104

ABSTRACT

OBJECTIVE: Sinonasal malignant tumors (SNMT) are relatively rare among head and neck malignant tumors. Most are squamous cell carcinomas, and malignant melanomas, olfactory neuroblastomas, adenoid cystic carcinomas, sarcomas, and others also occur. The most common primary site of nasal sinus squamous cell carcinoma is the maxillary sinus. In recent years, a decrease in incidence of maxillary sinus squamous cell carcinoma (MSSCC) has been reported along with a decrease in the incidence of sinusitis. MSSCC is treated with a combination of surgery, radiation, and chemotherapy. Treatment decisions are made according to the progression of the disease, the patient's general condition, and the patient's own wishes. There are variations in treatment policies among facilities due to the specialty of staff and cooperation with other departments at each facility. We conducted a multi-institutional retrospective study to compare outcomes by treatment strategy. METHODS: In this study, 340 patients with SNMT who were treated at 13 Hospitals (Head and Neck Oncology Group (Kyoto-HNOG) ) during the 12-year period from January 2006 to December 2017 were included. There were 220 patients with squamous cell carcinoma, 32 with malignant melanoma, 21 with olfactory neuroblastoma, and 67 with other malignancies. Of the squamous cell carcinomas, 164 were of maxillary sinus origin. One hundred and forty cases of MSSCC that were treated radically were included in the detailed statistical analysis. RESULTS: There were 5 cases of cStage I, 9 cases of cStage II, 36 cases of cStage III, 74 cases of cStage IVa, and 16 cases of cStage IVb. There were 92 cases without clinical lymph node metastasis (cN(-)) and 48 cases with clinical lymph node metastasis(cN(+)). Primary tumors were treated mainly by surgery in 85 cases (Surg) and by radical radiation therapy (with or without chemotherapy) of 6-70 Gy in 55 cases(non-Surg). The 5-year overall/disease-free survival rate (OS/DFS) for MSSCC was 65.1%/51.6%. Old age, renal dysfunction, and clinical T progression were independent risk factors for OS, and renal dysfunction was an independent risk factor for DFS. In cN(-) patients, OS and DFS were significantly better in Surg group than in non-Surg group. In cN(+) patients, there was no significant difference in OS and DFS between Surg and non-Surg groups. CONCLUSION: For patients with MSSCC without lymph node metastasis, aggressive surgery on the primary tumor contributes to improved prognosis.


Subject(s)
Carcinoma, Squamous Cell , Esthesioneuroblastoma, Olfactory , Kidney Diseases , Melanoma , Nose Neoplasms , Paranasal Sinus Neoplasms , Humans , Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/therapy , Esthesioneuroblastoma, Olfactory/therapy , Esthesioneuroblastoma, Olfactory/pathology , Lymphatic Metastasis , Melanoma/pathology , Nasal Cavity/pathology , Nose Neoplasms/epidemiology , Nose Neoplasms/therapy , Nose Neoplasms/pathology , Paranasal Sinus Neoplasms/pathology , Retrospective Studies , Squamous Cell Carcinoma of Head and Neck/therapy , Aged
5.
Head Neck ; 46(1): 118-128, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37897205

ABSTRACT

BACKGROUND: Late laryngopharyngeal cancers after transoral surgery include not only local recurrences but also metachronous multiple cancers. METHODS: We compared clinical information, surgical outcomes, and late laryngopharyngeal cancers in patients who underwent transoral nonrobotic surgery for laryngopharyngeal squamous cell carcinoma without lymph node metastases between 2015 and 2021 in a multicenter retrospective study. RESULTS: Four hundred and fifty-seven patients were included. Positive surgical margins were found in 121 patients (26.5%). Twenty-two patients (4.8%) received additional treatment. Positive horizontal margins of invasive carcinoma (p = 0.003) and positive horizontal margins of carcinoma in situ only (p = 0.032) were independent risk factors for local recurrence, and prior radiotherapy (p = 0.001) for metachronous multiple cancers. Local control was significantly worse without additional treatment (p = 0.049), but there was no significant difference in survival. CONCLUSIONS: Patients with positive margins had an increased frequency of local recurrence, but salvage therapy was effective.


Subject(s)
Carcinoma, Squamous Cell , Head and Neck Neoplasms , Hypopharyngeal Neoplasms , Humans , Squamous Cell Carcinoma of Head and Neck/surgery , Retrospective Studies , Carcinoma, Squamous Cell/surgery , Neoplasm Recurrence, Local/pathology
6.
Endocr J ; 70(10): 969-976, 2023 Oct 30.
Article in English | MEDLINE | ID: mdl-37635058

ABSTRACT

The operative procedure in the surgical treatment of parathyroid carcinoma differs from that of benign hyperparathyroidism. However, preoperative differentiation is often difficult. This study elucidated how clinicians diagnose parathyroid carcinoma and the relationship between preoperative diagnosis and the operative course. Using a retrospective chart review, twenty cases of parathyroid carcinoma from nine participating centers were examined. In 11 cases with preoperative suspicion of malignancy, at least one of these three features was found: elevated serum calcium level (>14 mg/dL), palpable mass, and irregular margin on ultrasonography. Although an intact parathyroid hormone (iPTH) threshold to suspect malignancy has not been established, six cases showed marked iPTH elevation exceeding 8.0 times the upper limit of normal. One case was excluded from analysis due to hemodialysis. Compared with the four cases that showed calcium elevation, the iPTH threshold might represent better sensitivity. Among 9 cases of benign preoperative diagnosis, six cases were performed with pericapsular resection. In three cases where malignancy was suspected in the middle of the operation, the recommended en bloc resection with ipsilateral thyroid lobectomy was not performed but a parathyroidectomy with surrounding soft tissue. In contrast, 10 preoperatively suspected cases underwent en bloc resection, and one case underwent pericapsular resection followed by supplementary ipsilateral hemithyroidectomy due to the uncertain pre- and intraoperative findings to determine the diagnosis. In conclusion, the surgical procedure for parathyroid carcinoma strongly depends on the preoperative diagnosis. The presence of excessive iPTH levels might contribute to improved preoperative diagnostic sensitivity for parathyroid carcinoma.


Subject(s)
Hyperparathyroidism , Parathyroid Neoplasms , Humans , Parathyroid Neoplasms/diagnosis , Parathyroid Neoplasms/surgery , Parathyroid Neoplasms/pathology , Calcium , Retrospective Studies , Parathyroid Hormone
7.
Head Neck ; 45(7): 1812-1822, 2023 07.
Article in English | MEDLINE | ID: mdl-37161880

ABSTRACT

BACKGROUND: Some oral squamous cell carcinoma (OSCC) cases are unaffected by smoking or drinking. This study aimed to clarify distinctive groups among OSCC patients and examine the characteristics of multiple primary carcinomas (MPCs). METHODS: We analyzed data from 970 patients. The patients were divided into three groups: all individuals <45 years (<45 y), smokers/drinkers ≥45 years (SD ≥45 y), and non-smokers/non-drinkers ≥45 years (NSND ≥45 y). RESULTS: Tongue cancers were more common in the <45 y group than in the other groups (p < 0.001). The NSND ≥45 y group was significantly older and more likely to be female than the SD ≥45 y group (p < 0.001). MPCs in the upper aerodigestive tract were more common in men and smokers/drinkers, whereas women were at risk for multiple primary OSCCs (p = 0.022). CONCLUSIONS: The "young tongue" and "elderly female" subgroups and characteristics of MPCs suggest carcinogenic factors of OSCC other than smoking and drinking.


Subject(s)
Carcinoma, Squamous Cell , Head and Neck Neoplasms , Mouth Neoplasms , Male , Humans , Female , Aged , Mouth Neoplasms/epidemiology , Mouth Neoplasms/etiology , Mouth Neoplasms/pathology , Squamous Cell Carcinoma of Head and Neck/epidemiology , Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/etiology , Carcinoma, Squamous Cell/pathology , Retrospective Studies , Alcohol Drinking/adverse effects , Alcohol Drinking/epidemiology , Smoking/adverse effects , Smoking/epidemiology
8.
Auris Nasus Larynx ; 50(4): 623-627, 2023 Aug.
Article in English | MEDLINE | ID: mdl-35606217

ABSTRACT

Supracricoid hemilaryngopharyngectomy (SCHLP) is a laryngeal preservation surgery for hypopharyngeal carcinoma confined to the pyriform sinus or laryngeal carcinoma with arytenoid infiltration. Postoperative dysphagia is inevitable, but both voice and swallowing functions can be preserved. Here, we present a case of severe dysphagia secondary to unexpected postoperative tissue loss and scarring. A 67-year-old man underwent left SCHLP for hypopharyngeal cancer, and on the third postoperative day, he developed necrotizing fasciitis of the left neck. He was unable to swallow and was transferred to a rehabilitation hospital 90 days after the surgery. Six months after surgery, the patient had significant glottic insufficiency due to laryngeal deformity, constant massive salivary aspiration, and difficulty releasing the cuffed cannula. Severe dysphagia due to glottic insufficiency and laryngeal elevation insufficiency due to scar formation were considered, and laryngoplasty and laryngeal suspension surgery using costal cartilage were performed on the 221st postoperative day. After the reoperation, he was able to wear a speech valve and could speak and spit out, although his glottis was still closed. On the 70th day after the reoperation, he was able to consume three meals of an oral dysphagia diet and was discharged home.


Subject(s)
Costal Cartilage , Deglutition Disorders , Hypopharyngeal Neoplasms , Laryngeal Neoplasms , Male , Humans , Aged , Deglutition , Deglutition Disorders/etiology , Deglutition Disorders/surgery , Hypopharyngeal Neoplasms/surgery , Laryngeal Neoplasms/surgery , Cricoid Cartilage/surgery , Laryngectomy
9.
Auris Nasus Larynx ; 49(5): 834-844, 2022 Oct.
Article in English | MEDLINE | ID: mdl-35232636

ABSTRACT

OBJECTIVE: Real-world outcomes and prognostic factors in Japanese patients receiving nivolumab therapy for recurrent or metastatic head and neck carcinoma (RMHNC) with an observation period of 1 year have been previously reported. The 1-year follow-up data have been subsequently accumulated, and the long-term real-world outcomes have been analyzed. This study aimed to investigate the 2-year long-term outcomes and prognostic factors associated with the response to nivolumab. METHODS: This was a multi-institutional retrospective study. In total, 88 RMHNC Japanese patients with squamous cell carcinoma who received nivolumab between May 2017 and May 2018 were retrospectively reviewed. Overall survival (OS), progression-free survival (PFS), and best overall response (BOR) were evaluated. Univariate and multivariable analyses were performed to identify the prognostic factors. RESULTS: The median follow-up periods for monitoring OS and PFS were 73.1 and 48.1 weeks, respectively. The median OS was 74.1 weeks, and the 2-year survival rate was 33.4%. The median PFS was 18.5 weeks, and the 2-year PFS rate was 22.5%. The BOR rate was 10.2%, 19.3%, 25.0%, and 44.3% in patients who achieved complete response, partial response, stable disease, and progressive disease (PD), respectively. Among the 88 patients with RMHNC, a total of 40 immune-related adverse events (irAEs) were reported in 30 patients. Four patients continued nivolumab, while 84 patients discontinued nivolumab at the data cut-off date. The most common reason for discontinuation was PD in 61 patients, irAEs in 14 patients, and patients' wishes in 7 patients. Of the 61 patients who discontinued nivolumab because of PD, 28 patients received subsequent treatment. Statistical analyses revealed radiotherapy history, performance status, platinum-refractory carcinoma, irAEs, age, and post-nivolumab treatment as the important prognostic factors associated with OS in patients with RMHNC, and the magnitude of BOR was significantly associated with OS. Additionally, patients with subsequent treatment, including molecular targeted therapy and/or chemotherapy, had significantly prolonged OS compared to patients without subsequent treatment in cases with nivolumab discontinuation because of PD. CONCLUSION: These findings could be a useful guide for future treatment strategies for head and neck carcinoma. Considering the limitations of our cohort, further larger-scale studies with long-term follow-up are needed to substantiate the results of this study.


Subject(s)
Carcinoma , Head and Neck Neoplasms , Head and Neck Neoplasms/drug therapy , Humans , Neoplasm Recurrence, Local/pathology , Nivolumab/therapeutic use , Prognosis , Retrospective Studies , Squamous Cell Carcinoma of Head and Neck/drug therapy
10.
J Voice ; 36(6): 770-776, 2022 Nov.
Article in English | MEDLINE | ID: mdl-32951954

ABSTRACT

OBJECTIVES: Cepstral analysis does not require the detection of pitch within waveforms, which makes it suitable for acoustic evaluation of connected speech contexts and severely disordered voice. Although the utility of cepstral measurements, including cepstral peak prominence (CPP) and cepstral spectral index of dysphonia (CSID), has been reported for several languages, it has yet to be demonstrated in the Japanese language. The current study aimed to investigate the utility of cepstral acoustic analysis for the Japanese language as an indicator of dysphonia and the degree of dysphonia severity. METHODS: Ninety-five patients with dysphonia and thirty volunteers without voice complaint uttered the sustained vowel /a/ and read four Japanese sentences designed to elicit different laryngeal behaviors. The recorded voice samples were evaluated perceptually by three raters according to the GRBAS scale (grade) and overall severity (OS) on a visual analog scale. Participants were then divided into four groups based on grade and OS: non-, mildly, moderately, and severely dysphonic groups. For the acoustic analysis, CPP and CSID were computed using the Analysis of Dysphonia in Speech and Voice, while jitter percentage (Jitt), shimmer percentage (Shim), and noise to harmonic ratio were computed using the Multi-Dimensional Voice Program. RESULTS: Statistical analysis revealed that both CPP and CSID differed significantly between all groups, except for grade between the non-dysphonic and mildly dysphonic groups. Pearson correlation analysis between the acoustic measurements and the perceptual ratings revealed that the absolute correlation coefficients for CPP, CSID, and Jitt were greater than 0.7. Specifically, those for CPP and CSID were greater than 0.8 for OS. Receiver operating characteristic curve analysis showed that the AUC for CPP, CSID, Jitt, and Shim was greater than 0.8 for both grade and OS. The cut-off values for CPP and CSID, as determined by the Youden Index, were 6.74-7.18 and 12.16-20.39, respectively. CONCLUSION: The current study demonstrated the validity of CPP and CSID as indicators of dysphonia and indices of dysphonia severity in the Japanese language.


Subject(s)
Dysphonia , Speech Perception , Humans , Dysphonia/diagnosis , Speech Acoustics , Voice Quality , Language , Japan , Severity of Illness Index , Acoustics , Speech Production Measurement/methods , Hoarseness
11.
Medicina (Kaunas) ; 57(12)2021 Dec 13.
Article in English | MEDLINE | ID: mdl-34946306

ABSTRACT

Background and Objectives: To investigate clinicopathological characteristics and survival outcomes of patients with buccal cancer in Japan. Materials and Methods: This study was conducted using a database of 1055 patients with oral cancers treated between 2010 and 2017 at 12 institutions in Japan. Ninety-two patients (8.7%) with primary buccal cancer were extracted and clinicopathological characteristics and survival outcomes were compared between patients with buccal cancers and patients with other oral cancers. Results: Ages were significantly higher in the patients with buccal cancer (73 years old vs. 69 years old). Buccal cancer had less advanced cT stage and cN stage than other oral cancers. Overall 5-year survival (OS) was 80.6%, and recurrence-free 5-year survival (RFS) of buccal cancers was 67.8%, and there were no significant differences in survival compared with other oral cancers in terms OS or RFS (5y-OS: 82.5%, 5y-RFS: 74.4%). However, patients with stage IV buccal cancer showed poorer prognosis in terms of OS and RFS compared with the same stage patients with other oral cancer. Advanced T stage was the only factor independently associated with both OS and RFS of patients with buccal cancer in this study. Conclusions: Postoperative radiotherapy or chemoradiotherapy should be considered to improve survival outcome of buccal cancer patients, especially for the patients with advanced primary site disease or a higher cancer stage.


Subject(s)
Carcinoma, Squamous Cell , Mouth Neoplasms , Aged , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/therapy , Chemoradiotherapy , Disease-Free Survival , Humans , Japan/epidemiology , Mouth Neoplasms/pathology , Mouth Neoplasms/therapy , Neoplasm Staging , Prognosis , Retrospective Studies
12.
Medicina (Kaunas) ; 57(4)2021 Apr 12.
Article in English | MEDLINE | ID: mdl-33921486

ABSTRACT

Backgrounds and Objectives: The epidemiology and prognostic role of lingual lymph node (LLN) metastasis in patients with oral squamous cell carcinoma (OSCC) remain unclear. Here, we aimed to analyze the clinicopathological features, risk factors, and prognostic role of LLN metastasis in patients with OSCC. Materials and Methods: In total, 945 patients with OSCC were retrospectively analyzed. Clinicopathological features were compared between patients with and without LLN metastasis. The risk factors of LLN metastasis and its effects on survival outcomes were evaluated using multi-variate analysis. Results: LLN metastasis was noted in 67 patients (7.1%). Habitual alcohol consumption and clinical neck node metastasis were independent risk factors for LLN metastasis. LLN metastasis was an independent prognostic factor for disease-free and overall survival, although LLN dissection did not improve survival outcomes. Conclusion: LLN metastasis is an independent adverse prognostic factor. Further prospective studies are needed to fully assess the extent of LLN dissection required in OSCC patients.


Subject(s)
Carcinoma, Squamous Cell , Head and Neck Neoplasms , Mouth Neoplasms , Carcinoma, Squamous Cell/pathology , Humans , Lymph Nodes/pathology , Lymphatic Metastasis , Mouth Neoplasms/pathology , Neoplasm Staging , Prognosis , Prospective Studies , Retrospective Studies , Squamous Cell Carcinoma of Head and Neck
13.
Auris Nasus Larynx ; 48(1): 148-153, 2021 Feb.
Article in English | MEDLINE | ID: mdl-32718811

ABSTRACT

OBJECTIVE: Postoperative radioactive iodine (RAI) adjuvant therapy improves the prognosis in patients with advanced papillary thyroid carcinoma (PTC), although the role of RAI adjuvant therapy remains unclear in intermediate-risk patients, as defined by the American Thyroid Association. The ATA cautiously recommended RAI adjuvant therapy in patients with T1-3N1b, but the Japanese Society of Thyroid Surgery suggests lobectomy without RAI adjuvant therapy in these patients. This study assessed the role and efficacy of RAI adjuvant therapy in patients with T1-3N1b PTC. METHODS: A single-center retrospective observational study was performed. We included patients with T1-3N1bM0 PTC who underwent complete resection between January 2003 and December 2017. Patients with bilateral PTC were excluded. We compared recurrence rates after surgery with RAI adjuvant therapy and surgery alone. RESULTS: A total of 61 patients (male:female ratio, 18:43; mean age, 57.1 ± 16.7 years) were included, and the median follow-up period was 6.8 years. Of the included patients, 33 were treated with surgery with RAI adjuvant therapy and 28 were treated with surgery alone. The RAI treatment group that underwent surgery had larger tumors, more lymph node metastases, and were younger. There were no disease-specific deaths, and 10 patients experienced local recurrence. The recurrence rate was 24.2% in patients who underwent surgery with RAI adjuvant therapy and 7.1% in patients who underwent surgery alone. Compared to T1-2 stage patients, the T3 stage patients tended to have a higher recurrence rate (odds ratio, 2.38; 95% confidence interval, 0.51-10.7). CONCLUSIONS: The recurrence rate was higher in patients who underwent surgery with RAI adjuvant therapy than in patients who underwent surgery alone. Patients in the former group had larger tumors and more lymph node metastases, and this difference in baseline characteristics could explain their higher recurrence rate. The recurrence rate was lower in patients with small tumors, and RAI adjuvant therapy would likely not play a major role in T1-2N1bM0 patients.


Subject(s)
Iodine Radioisotopes/therapeutic use , Radiotherapy, Adjuvant , Thyroid Cancer, Papillary/surgery , Thyroid Neoplasms/surgery , Aged , Disease-Free Survival , Female , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Neoplasm Recurrence, Local/surgery , Neoplasm Staging , Retrospective Studies , Risk Factors , Thyroid Cancer, Papillary/pathology , Thyroid Cancer, Papillary/radiotherapy , Thyroid Neoplasms/pathology , Thyroid Neoplasms/radiotherapy
14.
Ann Clin Epidemiol ; 3(3): 88-95, 2021.
Article in English | MEDLINE | ID: mdl-38505765

ABSTRACT

BACKGROUND: Primary curative treatment of resectable laryngeal cancer includes surgery and chemoradiotherapy. Other treatment options include radiotherapy, chemoradiotherapy, partial laryngectomy, and total laryngectomy. Larynx-preserving treatments (partial laryngectomy, radiotherapy, and chemoradiotherapy) are recommended in early stage cases, although total laryngectomy is needed in advanced cases. Here, we evaluated trends in treatment strategies and identified the factors that are important in decision making. METHODS: We performed a retrospective analysis of data acquired from electronic medical records in Japan. Hospitalized laryngeal cancer patients admitted between January 2014 and December 2018 were included in our analyses. The primary outcome was the initial treatment. RESULTS: A total of 363 patients (mean age 71.8 ± 9.5, male/female = 333/30) met the inclusion criteria. Of these, 10.1% of the patients were treated with total laryngectomy, while 17.9% underwent partial resection, 65.8% received radiotherapy (chemoradiotherapy), and 6.1% had no treatment. Larynx-preserving treatment was used in most T1-2 cases (96.9%), and 40% of the patients with T3 cancer underwent total laryngectomy (adjusted odds ratio 26.7 [95% CI, 9.29-91.6]). Of the T3 cancers that were treated, total laryngectomy was performed in only 26.7% of patients aged ≤65 years, but in more than 50% of those aged >65 years. CONCLUSIONS: This retrospective study showed that larynx-preserving treatments were used in most T1-2 cases, and suggested that T stage is the most important factor affecting decision making in the treatment of laryngeal cancer. Older patients with T3 disease tended to undergo total laryngectomy, and age is an important factor in the decision-making process for cases of T3 laryngeal cancer.

15.
Auris Nasus Larynx ; 47(1): 111-115, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31104870

ABSTRACT

OBJECTIVE: Salivary gland carcinoma is rare among head and neck cancers. Sublingual gland carcinoma, a type of salivary gland carcinoma, is even rarer; therefore, the number of cases at a single institute is too small for sufficient evaluation of tumor characteristics. We conducted a multicenter, retrospective analysis of sublingual gland carcinomas in patients who visited 12 institutions associated with the Kyoto Hospital and Affiliated Facilities Head and Neck Clinical Oncology Group. METHODS: Thirteen previously untreated patients who visited the institutions between 2006 and 2015 were enrolled. The overall survival (OS) and disease-free survival (DFS) rates for all patients and by disease stage were analyzed. Statistical analyses were performed for all patients with respect to disease stage. RESULTS: Eight of thirteen patients were diagnosed with adenoid cystic carcinoma on pathological study. A significant difference in OS rate was observed between patients with Stage I-III and Stage IV disease; however, the difference in DFS rate by disease stage was not significant. CONCLUSION: Stage IV disease was identified as a poor prognostic factor in patients with sublingual gland carcinoma. However, even patients with Stage I-III disease experienced relatively short DFS. Distant metastasis is a serious problem among patients with sublingual gland carcinoma.


Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Adenoid Cystic/therapy , Carcinoma, Mucoepidermoid/therapy , Otorhinolaryngologic Surgical Procedures , Radiotherapy , Sublingual Gland Neoplasms/therapy , Adenocarcinoma/pathology , Adenocarcinoma/secondary , Adenocarcinoma/therapy , Aged , Aged, 80 and over , Bone Neoplasms/secondary , Carcinoma, Adenoid Cystic/pathology , Carcinoma, Adenoid Cystic/secondary , Carcinoma, Mucoepidermoid/pathology , Carcinoma, Mucoepidermoid/secondary , Disease-Free Survival , Female , Humans , Japan , Lung Neoplasms/secondary , Lymph Nodes/pathology , Male , Middle Aged , Neck Dissection , Neoplasm Invasiveness , Neoplasm Staging , Prognosis , Radiotherapy, Adjuvant , Retrospective Studies , Sublingual Gland Neoplasms/pathology , Survival Rate
16.
Cancers (Basel) ; 11(9)2019 Sep 06.
Article in English | MEDLINE | ID: mdl-31500103

ABSTRACT

Recently, a global phase III study demonstrated that nivolumab markedly improved patient outcomes in recurrent or metastatic head and neck carcinoma (RMHNC). However, the efficacy of nivolumab in patients who are ineligible for clinical trials is unknown. We investigated nivolumab efficacy in real-world patients and prognostic factors associated with the response to nivolumab. This study was conducted at 11 institutes associated with Kyoto University and its Affiliated Hospitals-Head and Neck Oncology Group. In total, 93 patients with RMHNC who received nivolumab between May 2017 and May 2018 were retrospectively reviewed. Objective response rate (ORR), overall survival, and progression-free survival (PFS) were evaluated. Univariate and multivariate analyses were performed to identify prognostic factors. The ORRs in patients with squamous cell carcinoma (SCC) and non-SCC were 21.8% and 0%, respectively. In patients with SCC and non-SCC, the 1-year PFS rates were 28.7% and 8.9%, respectively. The hazard ratio (HR) for risk of PFS events (SCC versus non-SCC) was 2.28 (95% confidence interval: 1.21-4.1; log-rank p = 0.007). Univariate and multivariate analyses revealed radiotherapy history, platinum-refractory carcinoma, and treatment-related adverse events (TRAEs) as important prognostic factors associated with PFS in patients with SCC. In a real-world setting, non-SCC and platinum-refractory carcinoma were associated with a poorer prognosis, and a history of radiotherapy to the primary tumor, and the occurrence of TRAEs were associated with a better prognosis. These findings could be useful for clinicians and patients when selecting a treatment strategy.

17.
Otol Neurotol ; 40(8): 1101-1108, 2019 09.
Article in English | MEDLINE | ID: mdl-31290805

ABSTRACT

OBJECTIVES: To compare the efficacy and safety of high-dose corticosteroids (initial prednisolone [PSL] of 100 mg or more daily) and standard-dose corticosteroids (initial PSL of 50-60 mg) in patients with Bell's palsy. STUDY DESIGN: A systematic review and meta-analysis. DATA SOURCES: Medline, Embase, Cochrane Central Register of Controlled Trials, Ichushi-Web, Web of Science, and CINAHL, combined with data from ClinicalTrials.gov. STUDY SELECTION: Published and unpublished cohort studies comparing high- and standard-dose corticosteroids in adult patients with Bell's palsy were included. DATA EXTRACTION: Study characteristics (study design, patient's number), patient characteristics (sex, age, disease severity, prescription of antivirals), and outcomes (nonrecovery, any adverse effects). DATA SYNTHESIS: From the 1,974 identified articles, 8 studies were met eligible criteria. Of the included studies, the initial dose in high-dose corticosteroids regimens varied from 120 mg to 200 mg PSL daily. Compared with standard-dose corticosteroids, high-dose corticosteroids were associated with a significantly decreased nonrecovery at 6 months after disease onset (odds ratio 0.42, 95% confidence interval 0.22-0.80; very low quality) in patients with Bell's palsy. No severe adverse effects were observed in patients receiving high- or standard-dose corticosteroids. CONCLUSION: High-dose corticosteroids reduce nonrecovery in patients with Bell's palsy. The dose of high-dose corticosteroids was varied and further prospective study is needed to identify an adequate dose of corticosteroids in these patients.


Subject(s)
Anti-Inflammatory Agents/administration & dosage , Bell Palsy/drug therapy , Prednisolone/administration & dosage , Adrenal Cortex Hormones/administration & dosage , Adrenal Cortex Hormones/therapeutic use , Adult , Dose-Response Relationship, Drug , Female , Humans , Male , Prospective Studies
18.
Auris Nasus Larynx ; 45(5): 1014-1019, 2018 Oct.
Article in English | MEDLINE | ID: mdl-29548524

ABSTRACT

OBJECTIVE: Nasal and sinonasal inverted papilloma (IP) are rare benign tumors and have the potential to exhibit malignancy in approximately 10% of cases. This study aimed to analyze the clinical features of IP associated with malignancy. Furthermore, we reviewed our therapeutic strategy and the clinical course of malignant IP. METHODS: Overall, 70 patients with IP at our institution were retrospectively analyzed from April 2006 to December 2015; of these, six (9%) had associated malignancy. Data was collected on sex, age, presenting symptoms (nasal bleeding, rhinorrhea, facial or cheek pain, and nasal obstruction), bone destruction, and extent of disease on CT and MRI. Categorical data of patients with and without malignancy were compared using the chi-square test. A p value of <0.05 was considered statistically significant. Our therapeutic strategy for IP with malignancy, particularly the surgical procedure, i.e., the external incision or the endoscopic nasal approach, varied based on when the carcinoma was detected. In addition, we considered postoperative radiation therapy depending on histological examination. RESULTS: Nasal bleeding (p<0.001), pain (p=0.040), bone destruction (p<0.001), and extent of disease (p=0.026) on CT and MRI findings were significantly associated with malignancy. Carcinoma was diagnosed preoperatively in two (33%) and postoperatively in four patients (67%). We operated five patients (one case was not treated because of end-stage pancreatic cancer). Two patients underwent endoscopic sinus surgery (ESS) alone, two ESS plus Denker's method, and one ESS plus anterior craniotomy. Three patients underwent surgery only, and two patients received postoperative radiotherapy. The median follow-up period was 69.3 months. One patient died of the disease and the remaining patients are alive without recurrence. CONCLUSION: For IP patients exhibiting these clinical findings preoperatively, we should suspect complication with malignancy and plan a treatment. Even if postoperative histology does not confirm malignancy, we should ensure careful observation because of metachronous malignant transformation or the possibility to overlook small malignant lesions. Our result suggests that our strategy for malignant IP could be a reasonable option.


Subject(s)
Carcinoma, Squamous Cell/epidemiology , Nose Neoplasms/epidemiology , Papilloma, Inverted/epidemiology , Paranasal Sinus Neoplasms/epidemiology , Aged , Aged, 80 and over , Bone Diseases/epidemiology , Carcinoma, Squamous Cell/therapy , Epistaxis/epidemiology , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Nose Neoplasms/therapy , Otorhinolaryngologic Surgical Procedures , Pain/epidemiology , Papilloma, Inverted/therapy , Paranasal Sinus Neoplasms/therapy , Radiotherapy, Adjuvant , Retrospective Studies , Tomography, X-Ray Computed
19.
Auris Nasus Larynx ; 45(5): 1066-1072, 2018 Oct.
Article in English | MEDLINE | ID: mdl-29428494

ABSTRACT

OBJECTIVE: Clinical studies demonstrating the prognostic factors in submandibular gland carcinoma are limited because the tumor is relatively rare. The aim of this study was to identify clinical outcomes and prognostic factors in submandibular gland carcinoma. METHODS: The study included 65 patients with submandibular gland carcinoma who underwent initial surgical treatment at the Kyoto University and its affiliated hospitals. RESULTS: The 3-year overall survival (OS), disease specific survival, locoregional control (LRC), and no distant metastasis (NDM) rates were 74.2%, 74.2%, 90.0%, and 64.8%, respectively. In the current follow-up study, 16 patients died of the disease, 5 patients were alive with recurrence, 43 patients were alive without disease, and 1 patient died of unrelated disease without recurrence. All patients who died of the disease had developed distant metastasis. Based on univariate analysis, tumor grade (high grade) and lymph node metastases (≥N2) were significant prognostic factors for OS and LRC. It also revealed tumor grade (high grade), T classification (≥T3), and lymph node metastases (≥N2) were significant for distant metastasis. Multivariate analysis showed the following significant prognostic factors: lymph node metastases (≥N2) for OS, LRC, and NDM, and high tumor grade for NDM. CONCLUSION: Our study suggested death of submandibular gland carcinoma occurred mainly due to distant metastasis. The significant predictors of distant metastasis were lymph node metastases (≥N2) and tumor grade (high grade).


Subject(s)
Carcinoma/mortality , Submandibular Gland Neoplasms/mortality , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Adult , Aged , Aged, 80 and over , Carcinoma/pathology , Carcinoma/surgery , Carcinoma, Adenoid Cystic/mortality , Carcinoma, Adenoid Cystic/pathology , Carcinoma, Adenoid Cystic/surgery , Carcinoma, Mucoepidermoid/mortality , Carcinoma, Mucoepidermoid/pathology , Carcinoma, Mucoepidermoid/surgery , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/surgery , Disease-Free Survival , Female , Humans , Lymph Nodes/pathology , Lymphatic Metastasis , Male , Middle Aged , Multivariate Analysis , Myoepithelioma/mortality , Myoepithelioma/pathology , Myoepithelioma/surgery , Neoplasm Grading , Neoplasm Recurrence, Local/epidemiology , Neoplasm Staging , Prognosis , Radiotherapy, Adjuvant , Submandibular Gland Neoplasms/pathology , Submandibular Gland Neoplasms/surgery , Survival Rate
20.
Acta Otolaryngol ; 138(6): 590-596, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29310489

ABSTRACT

OBJECTIVES: The management of patients with cervical metastasis in head and neck cancer of unknown primary (HNCUP) remains controversial. This current multicenter retrospective study investigated the treatment outcomes of patients with HNCUP. METHODS: The study included patients who were treated curatively at 12 institutions in Japan from January 2006 to December 2015. RESULTS: Eighty patients with HNCUP were included. The median follow-up period was 34 months. The three-year overall survival (OS), disease-specific survival (DSS), regional relapse-free survival (RRFS), local progression-free survival (LPFS), and distant metastasis-free survival (DMFS) rates were 72.5%, 80.3%, 74.0%, 89.7%, and 86.9%, respectively. Nodal status was a significant factor for OS, DSS, RRFS, and DMFS; and extracapsular extension (ECE) was significant for OS and DSS. There was a distinct difference between the survival rates of patients with N1-2a and N2b-3 disease. RT was a significant positive factor for LPFS (3-year LPFS, RT 93.0% vs. no RT 83.0%, p = .043). CONCLUSIONS: For N2a as well as N1 disease without ECE, a single treatment modality, including ND or RT alone is acceptable. When ND alone is performed, thorough monitoring should be continued during follow-up to identify the emergence of the primary lesion.


Subject(s)
Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/secondary , Head and Neck Neoplasms/mortality , Head and Neck Neoplasms/secondary , Neoplasms, Unknown Primary/mortality , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/therapy , Female , Head and Neck Neoplasms/therapy , Humans , Japan/epidemiology , Male , Middle Aged , Neoplasms, Unknown Primary/therapy , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...